The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim

Status

Completed

Conditions

Neoplasm

Treatments

Drug: Beta-blockers

Drug: Telmisartan

Drug: Diuretics

Drug: ARB

Drug: ACEI

Study type

Observational

Funder types

Industry

Identifiers

NCT02215733

502.599

Details and patient eligibility

About

The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).

Enrollment

1,165,781 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD)

Exclusion criteria